[Mineralocorticoid receptor antagonists: A new therapeutic option for diabetic kidney disease].
- Resource Type
- Academic Journal
- Authors
- Girerd S; Département de néphrologie, CHRU de Nancy, Nancy, France - Centre d'investigation clinique-plurithématique (CIC-P) 1433, F-CRIN INI-CRCT - Essais cliniques cardiovasculaires et rénaux, CHRU de Nancy, Nancy, France - Inserm U1116, université de Lorraine, France.; Soulie M; Inserm, UMRS 1138, centre de recherche des Cordeliers, Sorbonne Université, université Paris Cité, Paris, France.; Barrera-Chimal J; Centre de recherche de l'hôpital Maisonneuve-Rosemont, faculté de médecine, Centre affilié à l'université de Montréal, Montréal, Québec, Canada.; Jaisser F; Centre d'investigation clinique-plurithématique (CIC-P) 1433, F-CRIN INI-CRCT - Essais cliniques cardiovasculaires et rénaux, CHRU de Nancy, Nancy, France - Inserm U1116, université de Lorraine, France - Inserm, UMRS 1138, centre de recherche des Cordeliers, Sorbonne Université, université Paris Cité, Paris, France.
- Source
- Publisher: EDK Country of Publication: France NLM ID: 8710980 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1958-5381 (Electronic) Linking ISSN: 07670974 NLM ISO Abbreviation: Med Sci (Paris) Subsets: MEDLINE
- Subject
- Language
- French
Diabetic kidney disease (DKD) and its associated cardiovascular morbidity represent a major complication in diabetic patients. Over the past two decades, several experimental studies have shown benefits of mineralocorticoid receptor (MR) antagonists on the cardiorenal outcomes in animal models of non-diabetic or diabetic kidney diseases. Here, we summarize the role of MR activation in promoting inflammatory and fibrotic mechanisms that contribute to DKD pathophysiology. We also review the key findings of two recent large clinical trials FIDELIO-DKD and FIGARO-DKD which showed for the first time a major benefit of the non-steroidal MR antagonist, finerenone, on renal and cardiac specific outcomes across the spectrum of DKD severity. We finally discuss the place of finerenone compared to other DKD therapeutic approaches.
(© 2023 médecine/sciences – Inserm.)